Objective To investigate the effect of the comprehensive treatment system for dry eye in combination with drugs in treating meibomian gland dysfunction（MGD）-related dry eye. Methods A total of 120 patients with MGD-related dry eye who visited our department from January 2019 to December 2020 were selected as the study subjects and randomly assigned to the observation group and the control group（n=60）. Patients in the control group received 0.3% sodium hyaluronate eye drops and tobramycin dexamethasone eye ointment

and patients in the observation group received the comprehensive treatment system for dry eye in combination with drugs on top of treatment in the control group. Ocular surface disease index（OSDI） scale

Schirmer I test（SIT） measurement

tear film breaking-up time（BUT）

corneal fluorescein staining（FL） score and adverse reactions were compared between the two groups before and after treatment. Results After treatment

the OSDI score

SIT value

BUT

and FL score of the two groups were improved compared with those before treatment

and the improvements of the observation group were better than those of the control group

and the differences were statistically significant（all P<0.05）. Meanwhile

no significant adverse reactions were observed among patients in the 2 groups during the treatment. Conclusion The comprehensive treatment system for dry eye in combination with drugs in treating MGD-related dry eye can promote tear secretion

prolong tear film BUT

improve the ocular surface status

and relieve ocular discomfort symptoms

with marked efficacy and no significant adverse reactions. These benefits hold promise for a wider application of this procedure.